Form 4: Roivant Sciences CEO Matthew Gline Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Matthew Gline, CEO of Roivant Sciences, reports a transaction involving the disposal of common shares to cover tax obligations related to vested RSUs.
Summary
- On October 20, 2024, Matthew Gline, CEO of Roivant Sciences Ltd., reported a change in beneficial ownership of the company's common shares.
- The transaction involved the disposal of 10,945 common shares at a price of $11.92 per share.
- This disposal was executed to cover tax withholding obligations related to the vesting and settlement of previously granted Restricted Stock Units (RSUs).
- Following the transaction, Gline directly owns 17,361,059 common shares.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to tax obligations, with no indication of positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard practice of covering tax obligations related to equity compensation.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is related to tax obligations and does not represent a significant change in ownership.
Key Dates
| Date | Description |
|---|---|
| 10/20/2024 | Date of transaction involving the disposal of common shares. |
| 10/22/2024 | Date of signature by Attorney-in-Fact for Matthew Gline. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.